A presynaptic role for FMRP during protein synthesis–dependent long-term plasticity in *Aplysia*

Sally M. Till,[1,5] Hsiu-Ling Li,[1,2] Maria Concetta Miniaci,[1,6] Eric R. Kandel,[1,2,3,7] and Yun-Beom Choi[1,4]

[1]*Department of Neuroscience, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA;* [2]*Howard Hughes Medical Institute, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA;* [3]*Kavli Institute for Brain Science, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA;* [4]*Department of Neurology, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA*

Loss of the Fragile X mental retardation protein (FMRP) is associated with presumed postsynaptic deficits in mouse models of Fragile X syndrome. However, the possible presynaptic roles of FMRP in learning-related plasticity have received little attention. As a result, the mechanisms whereby FMRP influences synaptic function remain poorly understood. To investigate the cellular locus of the effects of FMRP on synaptic plasticity, we cloned the *Aplysia* homolog of FMRP and find it to be highly expressed in neurons. By selectively down-regulating FMRP in individual *Aplysia* neurons at the sensory-to-motor neuron synapse reconstituted in co-cultures, we demonstrate that FMRP functions both pre- and postsynaptically to constrain the expression of long-term synaptic depression induced by repeated pulses of FMRF-amide. In contrast, FMRP has little to no effect on long-term synaptic facilitation induced by repeated pulses of serotonin. Since other components of signaling pathways involved in plasticity appear to be conserved between *Aplysia* and mammalian neurons, our findings suggest that FMRP can participate in both pre- and postsynaptic regulation of enduring synaptic plasticity that underlies the storage of certain types of long-term memory.

[Supplemental material is available for this article.]

Fragile X syndrome is the most common genetically inherited form of mental impairment and results from the loss of a single protein, FMRP, encoded by the *FMR1* gene (Penagarikano et al. 2007). FMRP is an RNA binding protein that is localized throughout the cell body and dendrites of neurons and is thought to regulate the translation of proteins required for synaptic plasticity, perhaps in an activity-dependent and local fashion (Bagni and Greenough 2005). In support of this idea, mice lacking FMRP have enhanced type 1 metabotropic glutamate receptor (mGluR)–dependent hippocampal long-term depression (LTD) (Huber et al. 2002), a form of plasticity that requires protein synthesis in the postsynaptic cell (Huber et al. 2001).

Despite increasing evidence regarding the postsynaptic dendritic function of FMRP, little is known about its role in the presynaptic neuron. Several findings suggest that the loss of FMRP also has presynaptic effects. For example, some Fragile X individuals exhibit structural changes in their brain that are indicative of abnormalities in both axon segregation and aberrant white matter connectivity (Barnea-Goraly et al. 2003; Haas et al. 2009). Similarly, in the hippocampus, axonal projections from granule cells in the dentate gyrus to CA3 pyramidal neurons are abnormal in *Fmr1* knockout mice (Ivanco and Greenough 2002; Mineur et al. 2002). In addition, several studies in flies and rodents have demonstrated that FMRP can localize to axons and presynaptic specializations (Feng et al. 1997a; Antar et al. 2006; Christie et al. 2009), and that altered levels of FMRP affect growth cone dynamics (Antar et al. 2006; Li et al. 2009a) and axonal morphology (Morales et al. 2002; Bureau et al. 2008), as well as synapse and circuit formation (Zhang et al. 2001; Hanson and Madison 2007; Bureau et al. 2008; Gibson et al. 2008). Furthermore, FMRP is predicted to bind several mRNAs coding for proteins that are localized to axons and are involved in path-finding and synaptic plasticity (Brown et al. 2001; Miyashiro et al. 2003; Zalfa et al. 2003; Darnell et al. 2004).

These examples suggest an additional presynaptic role for FMRP. Although presynaptic FMRP has been implicated in synaptic plasticity (Bureau et al. 2008; Gibson et al. 2008; Zhang et al. 2009), no direct test of the role of FMRP in presynaptic function in forms of long-term synaptic plasticity has been undertaken. To address this question, we have cloned the homolog of FMRP in *Aplysia californica* (ApFMRP) and have studied its regulatory role in long-term synaptic plasticity using *Aplysia* sensory-to-motor neuron co-cultures. This reduced preparation is capable of expressing multiple forms of long-term synaptic plasticity that underlie sensitization and habituation, two simple forms of learning in *Aplysia* (Montarolo et al. 1986, 1988; Rayport and Schacher 1986) and allows the selective manipulation of pre- and postsynaptic neurons. We find that in *Aplysia*, FMRP plays a modulatory role during the expression of long-term synaptic depression induced by repeated pulses of FMRF-amide. In addition, we identify a novel presynaptic locus for FMRP function and confirm a postsynaptic role of FMRP in *Aplysia* previously described in rodents.

Present addresses: [5]*Centre for Integrative Physiology, University of Edinburgh, Edinburgh EH8 9XD, UK;* [6]*Department of Experimental Pharmacology, University of Naples Federico II, 80131 Naples, Italy.* [7]*Corresponding author.*
E-mail erk5@columbia.edu; fax (212) 543-5204.
Article is online at http://www.learnmem.org/cgi/doi/10.1101/lm.1958811.

Results

Identification of an *Aplysia FMR1* homolog (*ApFMRI*)

ApFMR1 was cloned using a combination of degenerate primed PCR, RACE PCR-based cloning, and isolation of two overlapping clones from a cDNA library constructed from *Aplysia* central nervous system mRNA. The resulting full-length clone codes for a protein approximately 710 amino acids in length (Fig. 1A). Comparison of *Aplysia*, mammalian, and *Drosophila* Fragile X-related proteins reveals both marked conservation and potentially important differences (Fig. 1B). Overall, ApFMRP is 40% identical to human FMRP, with significantly higher conservation in regions containing identified functional domains. Importantly, ApFMRP contains all of the key domains found in the family of Fragile X-related proteins including RNA binding motifs and elements involved in subcellular localization. The amino-terminal region of FMRP mediates protein–protein interactions and contains two relatively well-conserved Tudor domains that are common to RNA binding proteins (Maurer-Stroh et al. 2003; Ramos et al. 2006). Human and *Aplysia* FMRP share ~39% identity in this region. The two KH domains in ApFMRP are ~60% identical to human FMRP and retain a conserved isoleucine residue that is important for FMRP function (De Boulle et al. 1993; Feng et al. 1997b; Darnell et al. 2005b; Zang et al. 2009). ApFMRP also contains an RGG box, a poorly defined domain that is involved in RNA binding (Kiledjian and Dreyfuss 1992). Homology scores between human and *Aplysia* FMRP in this region are relatively low because this domain is defined only as containing a high concentration of arginines and glycines. Furthermore, it is unclear whether there are multiple distinct RGG boxes in the carboxy-terminal region of ApFMRP or if this domain is merely expanded.

ApFMRI is alternatively spliced

Mammalian *FMR1* undergoes significant alternative splicing giving rise to at least 12 possible protein isoforms (Ashley et al. 1993; Verkerk et al. 1993). Interestingly, many of the *ApFMR1* clones identified during screening contained small insertions of variable lengths in the second KH domain. Analysis of genomic sequence between coding regions flanking these splice sites revealed that these insertions arise from alternative 5′ donor and 3′ acceptor splice sites in two adjacent exons (Fig. 2A). Alternative splicing at these positions does not shift the reading frame of downstream *ApFMR1* sequences and can produce six possible isoforms (Fig. 2B). These insertions give rise to amino acids that exhibit some identity to those coded for by exons 11 and 12 of mammalian *FMR1*, regions that are not present in other Fragile X-related genes, *FXR1* and *FXR2*, or in the *Drosophila FMR1* homolog (Siomi et al. 1995; Zhang et al. 1995; Wan et al. 2000; Kirkpatrick et al. 2001). Analysis of *Drosophila* genomic sequence in analogous regions revealed no conventional splice sites that could produce similar alternative splicing, nor are there genomic sequences that can potentially code for homologous insertions. This further underscores the similarity of *Aplysia* and mammalian FMRP.

ApFMRI is widely expressed

To determine the expression profile of ApFMRP isoforms among multiple tissues, *ApFMR1* was amplified from RNA harvested from different organs from adult *Aplysia* using isoform-specific primers. *ApFMR1* has a widespread expression pattern among various tissues, with abundant expression in neurons (Fig. 2C). This is consistent with *FMR1* expression in other species including flies, zebrafish, frogs, and mammals (Hinds et al. 1993; Wan et al. 2000; Tucker et al. 2004; Lim et al. 2005). In neurons, mRNA corresponding to ApFMRP isoform six is more abundant than other alternatively spliced forms as detected by semiquantitative RT-PCR (Fig. 2C). This finding is corroborated by quantification of the frequency of different isoforms identified among clones during *ApFMR1* screening; of 109 clones identified from CNS-derived cDNA, ApFMRP isoforms were represented as


Figure 1. Conservation among the Fragile X–related family of proteins. (*A*) Amino acid alignment of human FMRP and the *A. californica* homolog. Yellow and orange amino acids represent products of alternative splicing. (Green) Conserved isoleucines in KH domains. (Boldface) Amino acids coded for by human *FMR1* exon 12. (*B*) Alignment of human, *Drosophila*, and *Aplysia* Fragile X-related proteins reveal that ApFMRP contains all of the key structural elements found in human FMRP (hFMRP) including amino acids corresponding to regions that are absent in the Fragile X-related family members FXR1P and FXR2P. Scores are expressed as percent identity to hFMRP. (NLS) Nuclear localization signal; (KH) K homology domain; (NES) nuclear export signal; (RGG) arginine glycine box; (NoS) nucleolar signal sequence.

Figure 2. *ApFMR1* is alternatively spliced. (*A*) Alternatively spliced isoforms of *ApFMR1* result from alternate 5′ donor and 3′ acceptor splice sites of adjacent exons. (*B*) Schematic depiction of the resulting six possible isoforms and their relative abundance in neurons. (*C*) RT-PCR for specific *ApFMR1* isoforms demonstrates that they are expressed in various tissues including neurons. (*D*) *ApFMR1* is expressed equally well in *Aplysia* sensory and L7 motor neurons using single-cell RT-PCR. These results show the representative triplicates of the experiments performed (*n* = 6). The synaptic markers *ApSynapsin* and *ApGluR2* were used as internal controls (Li et al. 2009b).

follows: isoform 1: 36%; isoform 2: 5%; isoform 3: 4%; isoform 4: 4%; isoform 5: 1%; and isoform 6: 50%. Isoform 6 contains an insertion in the region of alternative splicing, which based on homology comparisons suggests that it is more like FMRP than the FXRs (Kirkpatrick et al. 2001).

Since *Aplysia* sensory-to-motor neuron co-cultures have been widely used for studies of long-term synaptic plasticity, we verified the expression of *ApFMR1* in these neurons using single-cell RT-PCR (Fig. 2D). Because each isoform varies only in a small region, it is not feasible to design nested primer pairs that are specific for each isoform. Thus, we adopted nested primer pairs that are common to all *ApFMR1* isoforms. We found that *ApFMR1* is expressed equally well in both *Aplysia* sensory and L7 motor neurons (Fig. 2D).

ApFMRP is distributed throughout neuronal cell bodies and neurites

In all species studied to date, the subcellular localization of FMRP has been predominantly cytoplasmic. Because antibodies to ApFMRP do not exist, we expressed the most abundant *ApFMR1* isoform in *Aplysia* CNS, isoform 6, as an ApFMRP-ECFP fusion protein to determine the subcellular localization of ApFMRP. *Aplysia* sensory neurons were injected with a DNA construct coding for either ECFP or an ApFMRPiso6–ECFP fusion protein and were imaged by confocal microscopy. Whereas ECFP labeled neurons uniformly (Fig. 3A), ApFMRPiso6–ECFP was found in the cell body and extended into neurites in a granular pattern reminiscent of FMRP localization in primary cultures of rodent neurons (Fig. 3B; Antar et al. 2005, 2006). These structures extend

throughout sensory cell neurites regardless of whether cells are cultured alone (Fig. 3B) or in the presence of postsynaptic target neurons (Fig. 3C).

Reduction of ApFMRP enhances long-term depression induced by FMRFamide

Although FMRP has been shown to play a role in several long-lasting forms of synaptic plasticity in mammals (Huber et al. 2002; Li et al. 2002; Koekkoek et al. 2005; Larson et al. 2005; Zhao et al. 2005; Desai et al. 2006; Nosyreva and Huber 2006; Lauterborn et al. 2007; Meredith et al. 2007; Wilson and Cox 2007; Hu et al. 2008; Shang et al. 2009; Auerbach and Bear 2010), the relative contribution of FMRP located in either the pre- or postsynaptic compartment has not been determined. Since *ApFMR1* is expressed throughout the *Aplysia* nervous system and pre- and postsynaptic cells can be selectively manipulated in sensory–motor neuron co-cultures, we have directly examined the role of both pre- and postsynaptic ApFMRP in regulating long-term synaptic plasticity. To deplete ApFMRP, we injected individual cultured neurons with an antisense oligonucleotide designed to selectively target and degrade all isoforms of *ApFMR1* mRNA (Supplemental Fig. S1).

To evaluate possible postsynaptic roles of ApFMRP, we injected motor neurons in sensory–motor neuron co-cultures with either an antisense oligonucleotide targeted against *ApFMR1*, a sense (control) oligonucleotide, or vehicle alone. We then induced protein synthesis-dependent long-term synaptic depression by stimulation with five pulses of 1 μM FMRF-amide. In cultures with motor neurons injected with vehicle alone or with a sense oligonucleotide, the mean amplitude of the EPSP in the sensory–motor neuron synapse decreased 24 h following repeated exposure to FMRF-amide (sense oligo [S] %EPSP, −18.45% ± 2.2%, *n* = 11; vehicle alone [V] %EPSP, −17.8% ± 4.11%, *n* = 15; Fig. 4A). In contrast, in cultures with motor neurons injected with *ApFMR1* antisense oligonucleotides, the decrease in mean EPSP amplitude 24 h after FMRF-amide treatment was significantly enhanced (%EPSP, −31.38% ± 4.14%, *n* = 16; *P* = 0.015 vs. V; *P* = 0.027 vs. S; Fig. 4A). Oligonucleotide injection did not affect EPSPs recorded 24 h post-injection in the absence of FMRF-amide treatment (V %EPSP, +5.29% ± 5.74%, *n* = 7; S %EPSP, +3.38% ± 6.16%, *n* = 8; antisense oligo [AS] %EPSP, +2.30% ± 3.62%, *n* = 10; *P* > 0.05), indicating that postsynaptic ApFMRP does not modulate basal synaptic transmission. The enhancement of long-term depression in *Aplysia* due to the depletion of *ApFMR1* is similar to findings in *Fmr1* knockout mice that identify enhanced forms of late-phase LTD in the hippocampus and cerebellum (Huber et al. 2002; Koekkoek et al. 2005) that are thought to have a predominantly postsynaptic mechanism of expression (Huber et al. 2001; Koekkoek et al. 2005).

To determine whether FMRP also has a presynaptic contribution to long-lasting forms of synaptic depression, we looked at the effect of injecting presynaptic sensory neurons in sensory–motor neuron co-cultures with an *ApFMR1* antisense oligonucleotide on

Figure 3. ApFMRPiso6–ECFP localization in *Aplysia* neurons. When expressed in isolated sensory neurons in culture, (*A*) ECFP uniformly fills the extent of neurites, but (*B*) ApFMRPiso6–ECFP forms granules that extend throughout neurites. (*C*) In sensory–motor neuron co-cultures, ApFMRPiso6–ECFP forms granules that extend throughout neurites of sensory neurons. Scale bar, 20 μm. Red boxes show higher magnification views with scale bar, 10 μm.

specific to long-lasting forms of depression. To test whether FMRP plays a postsynaptic role in short-term depression, we injected motor neurons in sensory–motor neuron co-cultures with either antisense oligonucleotide targeted against *ApFMR1*, a sense control oligonucleotide, or vehicle alone and induced short-term synaptic depression by stimulating co-cultures with a single 5-min pulse of 1 μM FMRF-amide. The mean amplitude of the EPSP in the sensory–motor neuron synapse decreased 5 min after exposure to one pulse of FMRF-amide (V %EPSP, −52.20% ± 4.69%, $n = 10$) and was unaffected by injection of antisense or sense oligonucleotides (S %EPSP, −58.00% ± 4.23%, $n = 8$; AS %EPSP, −58.11% ± 3.74%, $n = 9$; $P > 0.05$; Fig. 4C). Injection of motor neurons with oligonucleotide did not affect basal synaptic transmission in the absence of FMRF-amide treatment (V %EPSP, −11.75% ± 4.73%, $n = 4$; AS %EPSP, −13.2% ± 6.45%, $n = 5$; S %EPSP, −6.17% ± 7.64%, $n = 6$; $P > 0.05$). Similarly, we found that injection of either antisense oligonucleotides targeted against *ApFMR1* or control oligonucleotides into sensory neurons in sensory–motor neuron co-cultures had no effect on the mean amplitude of the EPSP in response to a single pulse of 1 μM FMRF-amide (V %EPSP, −52.13% ± 6.00%, $n = 8$; S, −56.55% ± 5.30%, $n = 11$; AS, −52.33% ± 8.40%, $n = 9$; $P > 0.05$; Fig. 4D). We again found that oligonucleotide injection into sensory neurons did not affect basal synaptic transmission in the absence of FMRF-amide treatment (V %EPSP, −2.71% ± 6.00%, $n = 7$; S, −12.57% ± 3.84%, $n = 7$; AS, −9.75% ± 8.35%, $n = 8$; $P > 0.05$). These results indicate that neither pre- nor postsynaptic ApFMRP contributes to short-term synaptic depression or basal synaptic transmission.

the expression of long-term synaptic depression induced by stimulation with five pulses of 1 μM FMRF-amide (Fig. 4B). Whereas the mean amplitude of the EPSP at the sensory–motor neuron synapse decreased 24 h following repeated exposure to FMRF-amide in cultures with sensory neurons injected with vehicle alone or with a sense control oligonucleotide (S %EPSP, −24.32% ± 7.35%, $n = 18$; V %EPSP, −21.67% ± 6.99%, $n = 18$), injection of sensory neurons with *ApFMR1* antisense oligonucleotides significantly enhanced the decrease in mean EPSP amplitude in response to FMRF-amide (%EPSP, −40.59% ± 3.62%, $n = 27$; $P = 0.024$ vs. V; $P = 0.048$ vs. S; Fig. 4B). Again, oligonucleotide injection did not affect basal synaptic transmission recorded 24 h post-injection in the absence of FMRF-amide treatment (V %EPSP, +0.77% ± 7.40%, $n = 13$; S %EPSP, +2.06% ± 3.93%, $n = 18$; AS %EPSP, +0.056% ± 7.19%, $n = 18$; $P > 0.05$).

Taken together, these results suggest a general role for FMRP in processes specific to regulating the maintenance of synaptic depression. Furthermore, while experiments in *Fmr1* knockout mice have not been able to distinguish pre- from postsynaptic roles of FMRP in hippocampal LTD, our data in *Aplysia* offer direct evidence for a presynaptic as well as a postsynaptic role for FMRP in long-term synaptic depression.

Reduction of ApFMRP does not affect FMRF-amide-induced short-term depression

We next asked whether ApFMRP has a general role in regulating processes that underlie synaptic depression or whether its role is

Synaptic facilitation induced by 5-HT is not changed by reduction of ApFMRP

Finally, we asked whether ApFMRP regulates processes underlying long-term synaptic plasticity in general or if it is specific to synaptic depression. We first asked whether ApFMRP plays a role in the induction of short-term facilitation induced by serotonin (5-HT). Postsynaptic motor neurons in sensory–motor neuron co-cultures were injected with an antisense oligonucleotide targeting *ApFMR1*, a sense control oligonucleotide, or vehicle alone, and short-term facilitation was induced by stimulation with a single 5-min pulse of 10 μM 5-HT. All groups demonstrated comparable increases in EPSP amplitude 5 min following exposure to 5-HT (V %EPSP, +88.11% ± 18.61%, $n = 9$; S %EPSP, +76.08% ± 16.40%, $n = 12$; AS %EPSP, +92.27% ± 14.13%, $n = 11$; $P > 0.05$; Fig. 5A). Oligonucleotide injection also did not affect basal synaptic transmission in the absence of 5-HT treatment (V %EPSP, −8.11% ± 4.9%, $n = 9$; S %EPSP, −2.80% ± 4.62%, $n = 10$; AS %EPSP, −9.80% ± 4.82%, $n = 10$; $P > 0.05$). Similarly, oligonucleotide injection into presynaptic sensory neurons in sensory–motor neuron co-cultures also did not affect short-term

Figure 4. Down-regulation of ApFMRP enhances long-term depression induced by FMRF-amide. Repeated exposure to FMRF-amide (1 μM) causes a long-term depression of synaptic transmission measured 24 h after induction. Injection of an *ApFMR1* antisense oligonucleotide (AS) into either post-synaptic motor neurons (*A*) or presynaptic sensory neurons (*B*) enhances FMRF-amide-induced long-term depression of synaptic transmission 24 h after induction, whereas injection of sense oligonucleotide (S) or vehicle alone (V) does not. In contrast, neither post- nor presynaptic injection of *ApFMR1* AS or S oligonucleotides affected short-term depression induced with a single 5-min pulse of 1 μM FMRF-amide (*C* and *D*, respectively). Oligonucleotide injections did not affect basal transmission recorded post-injection in the absence of FMRF-amide.

in the absence of 5-HT treatment (V %EPSP, $-6.78\% \pm 8.61\%$, $n = 9$; S %EPSP, $-0.83\% \pm 12.45\%$, $n = 6$; AS %EPSP, $-1.67\% \pm 6.36\%$, $n = 6$; $P > 0.05$), or long-term facilitation of EPSP amplitude 24 h following repeated exposure to 5-HT (V %EPSP, $+94.1\% \pm 12.58\%$, $n = 20$; S %EPSP, $+69.5\% \pm 13.94\%$, $n = 18$; AS %EPSP, $+65\% \pm 11.36\%$, $n = 17$; $P > 0.05$; Fig. 5D). The inability of the knockdown of ApFMRP to affect processes required for the induction or expression of LTF is similar to several findings in *Fmr1* knockout mice that have largely failed to identify a role of FMRP in multiple forms of hippocampal long-term potentiation (LTP) (Godfraind et al. 1996; Paradee et al. 1999; Li et al. 2002; Larson et al. 2005; but see Lauterborn et al. 2007; Hu et al. 2008; Shang et al. 2009; Auerbach and Bear 2010).

Discussion

Aplysia express a homolog of *FMR1*

Comparison with mammalian *FMR1* demonstrates that *ApFMR1* represents the *Aplysia* homolog of the Fragile X gene family. Consistent with expression profiles of *FMR1* orthologs in other species, *ApFMR1* appears to be widely expressed, with the highest levels of expression in central neurons, and relatively low, but significant levels in all other tissues tested. This pattern of expression is compatible with

potentiation induced by one pulse of 5-HT (V %EPSP, $+71.80\% \pm 19.69\%$, $n = 10$; S %EPSP, $+84.22\% \pm 13.30\%$, $n = 9$; AS %EPSP, $+68.30\% \pm 14.56\%$, $n = 10$; $P > 0.05$) or basal synaptic transmission (V %EPSP, $-10.67\% \pm 5.19\%$, $n = 9$; S %EPSP, $-8.25\% \pm 5.62\%$, $n = 8$; AS %EPSP, $-0.27\% \pm 4.46\%$, $n = 15$; $P > 0.05$; Fig. 5A). These results indicate that neither pre- nor postsynaptic ApFMRP modulates the induction of short-term facilitation by 5-HT.

We next addressed whether ApFMRP has a role in the long-term facilitation induced by repeated exposure to 5-HT. Motor neurons in sensory–motor neuron co-cultures were injected with an antisense oligonucleotide targeted to *ApFMR1*, a sense oligonucleotide, or vehicle alone, and long-term potentiation was induced by stimulation with five pulses of 10 μM 5-HT. All groups demonstrated comparable increases in EPSP amplitude 24 h following exposure to 5-HT (V %EPSP, $+63.14\% \pm 12.09\%$, $n = 7$; S %EPSP, $+67.90\% \pm 24.45\%$, $n = 10$; AS %EPSP, $+58.54\% \pm 7.95\%$, $n = 13$; $P > 0.05$), and oligonucleotide injection did not affect basal synaptic transmission recorded at 24 h in the absence of 5-HT treatment (V %EPSP, $-3.0\% \pm 5.15\%$, $n = 8$; S %EPSP, $-1.43\% \pm 7.64\%$, $n = 7$; AS %EPSP, $-3.33\% \pm 7.50\%$, $n = 6$; $P > 0.05$; Fig. 5C). Similarly, injection into the presynaptic sensory neuron did not affect basal synaptic transmission recorded at 24 h

Figure 5. Down-regulation of ApFMRP does not affect long-term facilitation induced by 5-HT. Short-term facilitation was induced with one 5-min pulse of 10 μM 5-HT. The mean amplitude of the EPSP in the sensory–motor neuron synapse increased 5 min after exposure to 5-HT and was unaffected by injection of antisense (AS) or sense (S) *ApFMR1* oligonucleotides into postsynaptic motor neurons (*A*) or presynaptic sensory neurons (*B*). Repeated exposure to 5-HT (10 μM) causes a long-term facilitation of synaptic transmission measured 24 h after induction. Injection of antisense (AS) or sense (S) *ApFMR1* oligonucleotides into postsynaptic motor neurons (*C*) or presynaptic sensory neurons (*D*) did not change 5-HT-induced long-term facilitation of synaptic transmission 24 h after induction. Oligonucleotide injections did not affect basal transmission recorded post-injection in the absence of 5-HT.

findings in vertebrates and flies (Hinds et al. 1993; Schenck et al. 2001; Tucker et al. 2004; Lim et al. 2005).

The characterization of several cDNAs identified during screening for ApFMRP did not identify additional Fragile X-related transcripts in *Aplysia*, nor did analysis of more than 190,000 ESTs from *Aplysia* CNS libraries (Moroz et al. 2006). Given the degree of sequence homology in the FMRP KH domains among multiple species, it is unlikely that these cloning methods would have missed additional family members. Thus, it appears that, as with the *Drosophila* FMRP homolog (Wan et al. 2000), a single gene in *Aplysia* represents the family of vertebrate Fragile X-related proteins. The theory of gene duplication as a major genetic force permitting the evolution of vertebrates from invertebrates (Ohno 1970) is now generally accepted, and it is not uncommon for invertebrate genomes to contain single genes that are orthologous to entire vertebrate gene families (e.g., Araki et al. 1996; Stock et al. 1997). This single gene in invertebrates has most likely evolved via duplication to give rise to the Fragile X-related family of genes in mammals.

ApFMRP contains three distinct classes of highly conserved RNA binding domains that are characteristic of Fragile X-related proteins in other species: Tudor, KH, and RGG box domains. These regions share significant similarity with human FMRP in regions that confer RNA binding capacity, including the conservation of isoleucine residues important for FMRP KH domain function. ApFMRP is also homologous to the Fragile X-related proteins in regions involved in ribosome association and protein–protein interactions. In addition, the ApFMRP–ECFP fusion protein forms granular structures that are distributed throughout the neurites of cultured *Aplysia* neurons in a pattern similar to the distribution of mammalian FMRP in dendrites (Antar et al. 2005, 2006; Ferrari et al. 2007). The subcellular distribution and these RNA binding domains are central to the function of FMRP in processes including its regulation of RNA stability (Zalfa et al. 2007), transport and trafficking (De Diego Otero et al. 2002; Antar et al. 2005; Ferrari et al. 2007), and association with polyribosomes (Khandjian et al. 1996; Tamanini et al. 1996; Corbin et al. 1997; Feng et al. 1997b; Stefani et al. 2004; Darnell et al. 2005a). The dendritic and synaptic localization of FMRP (Feng et al. 1997b; Ferrari et al. 2007) and its association with mRNAs coding for proteins involved in synaptic plasticity (Zalfa et al. 2003; Iacoangeli et al. 2008) and synthesized in response to synaptic signals (Park et al. 2008; Waung et al. 2008) support a role for FMRP in local protein synthesis at the synapse, a cellular process thought to underlie changes in the morphology and stability of synapses associated with the expression of long-term plasticity (Martin and Zukin 2006). Indeed, studies in rodents have identified the importance of the KH2 RNA binding domain in the formation of dendritically localized FMRP granules (Darnell et al. 2005a) and elimination of dendritic spines (Pfeiffer and Huber 2007), as well as alterations in synaptic plasticity and behaviors associated with the loss of FMRP function in mice (Zang et al. 2009).

Further characterization of ApFMRP may provide valuable insight into the function of human FMRP. Human FMRP contains a stretch of amino acids encoded by exons 11 and 12 that are unique among the Fragile X-related family of proteins. While vertebrate FXRP proteins and the *Drosophila* Fragile X homolog do not contain these sequences, several alternatively spliced neuronal isoforms of ApFMRP contain inserts exhibiting some homology to amino acids in this unique region. Structure studies of mammalian FMRP and other proteins containing KH domains suggest that these extra amino acids are part of a variable loop region in the second KH domain of FMRP that contains charged residues in an exposed position (Valverde et al. 2007). Whereas little is known about the function of this loop, its inclusion appears to alter the affinity of FMRP for certain RNA targets (Denman and

Sung 2002; Xie et al. 2009), and alternative splicing in this region may serve to increase the functional diversity of FMRP by affecting its RNA binding and target recognition properties. In addition, since the FXRPs lack these sequences and do not appear to function as repressors of protein synthesis in vitro (Laggerbauer et al. 2001), this loop may also affect FMRP-mediated regulation of translation.

FMRP function in synaptic plasticity

To begin to study the pre- and postsynaptic roles of FMRP in long-term plasticity, we used a reduced neuronal culture system that reconstitutes critical components of the circuitry underlying a simple form of behavioral learning in *Aplysia*. Similar to findings that long-term depression is enhanced in mice lacking FMRP (Huber et al. 2002; Koekkoek et al. 2005), we find that injection of individual cultured neurons with an antisense oligonucleotide designed to selectively target and degrade *ApFMR1* mRNA leads to an enhancement of FMRF-amide-induced long-term depression. In contrast, antisense oligonucleotide injection does not affect long-term facilitation induced by repeated exposure to 5-HT at these synapses. This result is consistent with findings from several studies that suggest some forms of hippocampal long-term potentiation are unaffected in *Fmr1* knockout mice (Godfraind et al. 1996; Paradee et al. 1999; Li et al. 2002; Larson et al. 2005). Together, these studies highlight the similarities between forms of long-term plasticity in *Aplysia* and the mammalian hippocampus and suggest that FMRP normally functions to regulate molecules critical for the expression of long-term synaptic depression.

What may underlie the context specificity of the effect of FMRP knockdown on the expression of these forms of long-term plasticity? One possibility is that FMRF-amide induction of protein synthesis-dependent LTD specifically recruits signaling pathways that engage FMRP, for example, mGluR signaling. If 5-HT induction of LTF does not require the same signaling pathways, FMRP may not be recruited. Alternatively, FMRP may regulate the synthesis of a subset of mRNAs that are specifically required for the expression of LTD, but not LTF. Indeed, a recent study suggests that local protein synthesis can be both transcript- and stimulus-specific (Wang et al. 2009).

Whereas FMRP knockdown did not affect protein synthesis-dependent LTF induced by 5-HT, it remains a possibility that FMRP is involved in other forms of long-lasting synaptic facilitation. For example, some forms of LTP are altered in the cortex (Li et al. 2002; Larson et al. 2005; Zhao et al. 2005; Meredith et al. 2007; Wilson and Cox 2007; Harlow et al. 2010) and in the hippocampus (Lauterborn et al. 2007; Hu et al. 2008; Shang et al. 2009; Auerbach and Bear 2010) of *Fmr1* knockout mice. It is known that distinct forms of long-term plasticity can have different mechanisms underlying their expression. Furthermore, it is possible that the function of FMRP varies in a neuron- or synapse-specific manner, depending on the signaling pathways required for the induction or expression of distinct forms of plasticity, as well as the developmental stage of the animal. Alternatively, distinct molecular profiles of populations of cells or individual synapses may influence the regulation of FMRP or the availability of its RNA targets.

What is the locus for the influence of FMRP on synaptic plasticity? Previous investigations of synaptic depression in *Fmr1* knockout mice have suggested a postsynaptic role for FMRP by regulating mGluR-stimulated protein synthesis (Huber et al. 2001; Koekkoek et al. 2005). While our findings confirm a postsynaptic role of FMRP in the expression of protein synthesis-dependent long-term depression in *Aplysia*, they also demonstrate an additional presynaptic role for FMRP in this persistent form of plasticity. Since other mechanisms underlying plasticity appear to

be conserved between *Aplysia* and mammalian neurons (Pittenger and Kandel 2003), it is tempting to suggest that FMRP may also have a coordinated pre- and postsynaptic role in regulating some forms of long-term plasticity in the mammalian brain. For example, although the form of type 1 mGluR-dependent hippocampal LTD that is enhanced in *Fmr1* knockout mice has been shown to require de novo protein synthesis in dendrites (Huber et al. 2001), a presynaptic locus has not been directly investigated, but does contribute to other forms of mGluR-dependent LTD in the hippocampus (Zakharenko et al. 2002; Feinmark et al. 2003). Moreover, while the major postsynaptic mechanism for this form of mGluR-LTD is thought to be the internalization of postsynaptic AMPA receptors (Snyder et al. 2001), the levels of AMPA receptor surface expression in acute hippocampal slices from *Fmr1* knockouts appear to be comparable to controls in both basal conditions and following the induction and expression of mGluR-LTD (Nosyreva and Huber 2006). The discrepancy between these results could be accounted for by a presynaptic mechanism, such as the one we describe here for *Aplysia*, that also contributes to the enhanced expression of this form of plasticity in *Fmr1* knockout mice.

What, then, are the mechanisms by which FMRP regulates FMRF-amide-induced LTD presynaptically? Putative mRNA targets of FMRP have been identified that code for proteins important for presynaptic function, including munc13 and PP2A, as well as mRNAs coding for proteins important for normal axonal morphology, including MAP1b (Darnell et al. 2001; Castets et al. 2005). As FMRP is able to interact with or regulate the production of factors involved in structural rearrangements (Brown et al. 2001; Darnell et al. 2001; Schenck et al. 2001; Zhang et al. 2001; Miyashiro et al. 2003), it is possible that one or more of those factors is needed for the structural rearrangements leading to synapse destabilization or elimination that is associated with long-term depression (Bailey and Chen 1983, 1988; Bailey et al. 1992). In addition, since FMRP appears to inhibit the translation of its target RNAs (Laggerbauer et al. 2001; Li et al. 2001; Mazroui et al. 2002), it is possible that FMRP normally represses the synthesis of one of the proteins needed for expression of LTD, perhaps via mechanisms involving recruitment of RNAi machinery (Siomi et al. 2004) or interactions with the 4E-BP-like repressor of translation CYFIP1 (Napoli et al. 2008). In this model, down-regulation of FMRP removes an inhibitory constraint on this form of plasticity by increasing the translation of specific mRNAs necessary for long-term plasticity leading to enhanced LTD.

Finally, what might be the relationship between the cognitive impairment and abnormal immature-looking dendritic spines observed in Fragile X individuals and the enhancement of LTD observed following knockdown of FMRP in animal models? It is possible that enhanced LTD leading to enhanced synapse elimination (Bailey and Chen 1983, 1988; Bailey et al. 1992) can slow down the synaptic maturation, resulting in immature-looking dendritic spines and cognitive impairment (Pfeiffer and Huber 2007).

Materials and Methods

Cloning of ApFMRP

Total RNA was extracted from *Aplysia* pleural and pedal ganglia with Trizol (Invitrogen), and cDNA was synthesized with the Stratascript First Strand cDNA Synthesis Kit (Stratagene). Degenerate primers for PCR were designed against two regions of homology in the Fragile X-related proteins among multiple species: IUPAC code sequences from the KH2 domain corresponding to KVIGKNG (AARGTNATHGGNAARAAYGG) and KEVEQLR (GKNARYTGYTCNACYTCYTT). Bands of predicted size were

subcloned into vector PCR2.1 using TOPO-TA cloning (Invitrogen). Similarity to Fragile X-related proteins was determined using the BLAST search program (NCBI).

The 5′ end of *ApFMR1* cDNA was identified using the SMART RACE cDNA amplification system (Clontech). To identify the entire ApFMRP coding region, the 5′ half of the *ApFMR1* cDNA was then used to screen a phage cDNA library made from *Aplysia* central nervous system (a gift from Dusan Bartsch). Homology was determined using ClustalW alignments with Fragile X-related proteins from other species: hFMRP accession number NP_002015, hFXR1P accession number EAW78371, hFXR2P accession number NP_004851, and dFXRP accession number NP_731443. Scores are measures of amino acid identity and are calculated as percent identity of a length of sequence.

Subcloning

For expression of ApFMRPiso6–ECFP in *Aplysia* neurons, *ApFmr1* full-length cDNA was amplified from *Aplysia* cDNA using primers HindIII–FMRstart (CCCAAGCTTCGATGGAGGATCTTTCGGTT GAAATC) and FMRstop–BamHI (CGGGATCCCTATTCCCCATT CACTATATGCTC) and cloned into the HindIII/BamHI sites of pECFP-C1 (Clontech). An NheI/BamHI fragment from pECFPC1–ApFMR1 was subcloned into XbaI/BamHI sites in *Aplysia* expression vector pNEX3.

RT-PCR

RNA was extracted from multiple tissues using RNAqueous-4-PCR (Ambion), and RT-PCR was performed using HF-PROSTAR RT-PCR kit (Stratagene) with 50 ng of total RNA per reaction and an ApFMRP universal reverse primer (RT-QAKLE R: TTCCAGTTTGG CTTGCCG) and isoform unique forward primers (iso1: AGGGAA GAGGGTCAGGTA; iso2: AGACAACATGGGTCAGGTA; iso3: TGTTGAACTGGGTCAGGTA; iso4: GTTGAACTGGCCTCTTTCT; iso5: AGACAACATGGCCTCTTTCT; iso6: AGGGAAGAGGCC TCT-TTC).

Single-cell RT-PCR was performed as previously described (Li et al. 2009b). The nested primer pairs are as follows: F1: CAGCG GAGACGAAGGAGGAAAAAC; F2: AGGAGGAAAAACCGTCCC CGAGGC; R1: GGCCCCTGAAGTGGCCGACGCAGT; R2: GGCCGACGCAGTCGCAGAGCTGTT.

Oligonucleotide and plasmid DNA injection

Antisense oligonucleotides were chosen from nucleotide sequence contained in all isoforms of *ApFMR1* that exhibited the lowest degree of homology to entries in the nonredundant BLAST database; antisense: GTCTTGGATGTTCCGCCCAT; sense: ATGGGCGGAACATCCAAGAC. DNA constructs for injection were purified by equilibrium centrifugation in CsCl–ethidium bromide gradients (Sambrook et al. 1989). DNA and oligonucleotides were dissolved in water and diluted to a concentration of 25 ng/uL (oligo) and 1 μg/uL (DNA) in injection buffer (10 mM Tris-HCl at pH 7.6, 100 mM KCl, 0.1% fast green) and were pressure-injected into motor and sensory neurons with a pico-spritzer (General Valve) as previously described (Kaang 1996). Oligonucleotides were injected 3 h prior to FMRF-amide or 5-HT treatment.

Sensory and motor neuron co-cultures and electrophysiology

Co-cultures of sensory neurons and the motor neuron L7 of *Aplysia californica* were prepared as previously described (Montarolo et al. 1988). Electrical recordings were made from motor neurons using intracellular microelectrodes filled with 2.5 M KCl using an Axoclamp-2A amplifier. EPSPs were evoked by stimulating the sensory neurons extracellularly with depolarizing pulses as previously described (Montarolo et al. 1986).

Confocal imaging

Fluorescent images of sensory neurons expressing injected DNA constructs were acquired with Zeiss Axiovert microscopes mounted on an LSM Pascal (Zeiss) laser confocal scanning microscope. Images were taken with a $40 \times$, NA 0.75 (MRC1000) objective, and the gains and neutral density filters were adjusted to prevent saturation of the detection threshold.

Statistical analysis

All data are presented as mean percentage change $\pm$ SEM in the EPSP amplitude as compared to the initial amplitude. A two-factor (treatment/oligo) ANOVA and post hoc Fisher's LSD test were used for multiple comparisons.

Acknowledgments

References

Antar LN, Dictenberg JB, Plociniak M, Afroz R, Bassell GJ. 2005. Localization of FMRP-associated mRNA granules and requirement of microtubules for activity-dependent trafficking in hippocampal neurons. *Genes Brain Behav* **4:** 350–359.

Antar LN, Li C, Zhang H, Carroll RC, Bassell GJ. 2006. Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. *Mol Cell Neurosci* **32:** 37–48.

Araki I, Terazawa K, Satoh N. 1996. Duplication of an amphioxus myogenic bHLH gene is independent of vertebrate myogenic bHLH gene duplication. *Gene* **171:** 231–236.

Ashley CT, Sutcliffe JS, Kunst CB, Leiner HA, Eichler EE, Nelson DL, Warren ST. 1993. Human and murine FMR-1: Alternative splicing and translational initiation downstream of the CGG-repeat. *Nat Genet* **4:** 244–251.

Auerbach BD, Bear MF. 2010. Loss of the fragile X mental retardation protein decouples metabotropic glutamate receptor dependent priming of long-term potentiation from protein synthesis. *J Neurophysiol* **104:** 1047–1051.

Bagni C, Greenough WT. 2005. From mRNP trafficking to spine dysmorphogenesis: The roots of fragile X syndrome. *Nat Rev Neurosci* **6:** 376–387.

Bailey CH, Chen M. 1983. Morphological basis of long-term habituation and sensitization in *Aplysia*. *Science* **220:** 91–93.

Bailey CH, Chen M. 1988. Long-term memory in *Aplysia* modulates the total number of varicosities of single identified sensory neurons. *Proc Natl Acad Sci* **85:** 2373–2377.

Bailey CH, Montarolo P, Chen M, Kandel ER, Schacher S. 1992. Inhibitors of protein and RNA synthesis block structural changes that accompany long-term heterosynaptic plasticity in *Aplysia*. *Neuron* **9:** 749–758.

Barnea-Goraly N, Eliez S, Hedeus M, Menon V, White CD, Moseley M, Reiss AL. 2003. White matter tract alterations in fragile X syndrome: Preliminary evidence from diffusion tensor imaging. *Am J Med Genet B Neuropsychiatr Genet* **118:** 81–88.

Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, Jin X, Feng Y, Wilkinson KD, Keene JD, et al. 2001. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. *Cell* **107:** 477–487.

Bureau I, Shepherd GM, Svoboda K. 2008. Circuit and plasticity defects in the developing somatosensory cortex of FMR1 knock-out mice. *J Neurosci* **28:** 5178–5188.

Castets M, Schaeffer C, Bechara E, Schenck A, Khandjian EW, Luche S, Moine H, Rabilloud T, Mandel JL, Bardoni B. 2005. FMRP interferes with the Rac1 pathway and controls actin cytoskeleton dynamics in murine fibroblasts. *Hum Mol Genet* **14:** 835–844.

Christie SB, Akins MR, Schwob JE, Fallon JR. 2009. The FXG: A presynaptic fragile X granule expressed in a subset of developing brain circuits. *J Neurosci* **29:** 1514–1524.

Corbin F, Bouillon M, Fortin A, Morin S, Rousseau F, Khandjian EW. 1997. The fragile X mental retardation protein is associated with poly(A)$^+$ mRNA in actively translating polyribosomes. *Hum Mol Genet* **6:** 1465–1472.

Darnell JC, Jensen KB, Jin P, Brown V, Warren ST, Darnell RB. 2001. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. *Cell* **107:** 489–499.

Darnell JC, Warren ST, Darnell RB. 2004. The fragile X mental retardation protein, FMRP, recognizes G-quartets. *Ment Retard Dev Disabil Res Rev* **10:** 49–52.

Darnell JC, Mostovetsky O, Darnell RB. 2005a. FMRP RNA targets: Identification and validation. *Genes Brain Behav* **4:** 341–349.

Darnell JC, Fraser CE, Mostovetsky O, Stefani G, Jones TA, Eddy SR, Darnell RB. 2005b. Kissing complex RNAs mediate interaction between the Fragile-X mental retardation protein KH2 domain and brain polyribosomes. *Genes Dev* **19:** 903–918.

De Boulle K, Verkerk AJ, Reyniers E, Vits L, Hendrickx J, Van Roy B, Van den Bos F, de Graaff E, Oostra BA, Willems PJ. 1993. A point mutation in the FMR-1 gene associated with fragile X mental retardation. *Nat Genet* **3:** 31–35.

De Diego Otero Y, Severijnen LA, van Cappellen G, Schrier M, Oostra B, Willemsen R. 2002. Transport of fragile X mental retardation protein via granules in neurites of PC12 cells. *Mol Cell Biol* **22:** 8332–8341.

Denman RB, Sung YJ. 2002. Species-specific and isoform-specific RNA binding of human and mouse Fragile X mental retardation proteins. *Biochem Biophys Res Commun* **292:** 1063–1069.

Desai NS, Casimiro TM, Gruber SM, Vanderklish PW. 2006. Early postnatal plasticity in neocortex of Fmr1 knockout mice. *J Neurophysiol* **96:** 1734–1745.

Feinmark SJ, Begum R, Tsvetkov E, Goussakov I, Funk CD, Siegelbaum SA, Bolshakov VY. 2003. 12-Lipoxygenase metabolites of arachidonic acid mediate metabotropic glutamate receptor-dependent long-term depression at hippocampal CA3-CA1 synapses. *J Neurosci* **23:** 11427–11435.

Feng Y, Gutekunst CA, Eberhart DE, Yi H, Warren ST, Hersch SM. 1997a. Fragile X mental retardation protein: Nucleocytoplasmic shuttling and association with somatodendritic ribosomes. *J Neurosci* **17:** 1539–1547.

Feng Y, Absher D, Eberhart DE, Brown V, Malter HE, Warren ST. 1997b. FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association. *Mol Cell* **1:** 109–118.

Ferrari F, Mercaldo V, Piccoli G, Sala C, Cannata S, Achsel T, Bagni C. 2007. The Fragile X mental retardation protein-RNP granules show an mGluR-dependent localization in the post-synaptic spines. *Mol Cell Neurosci* **34:** 343–354.

Gibson JR, Bartley AF, Hays SA, Huber KM. 2008. Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of Fragile X syndrome. *J Neurophysiol* **100:** 2615–2626.

Godfraind JM, Reyniers E, De Boulle K, D'Hooge R, De Deyn PP, Bakker CE, Oostra BA, Kooy RF, Willems PJ. 1996. Long-term potentiation in the hippocampus of fragile X knockout mice. *Am J Med Genet* **64:** 246–251.

Haas BW, Barnea-Goraly N, Lightbody AA, Patnaik SS, Hoeft F, Hazlett H, Piven J, Reiss AL. 2009. Early white-matter abnormalities of the ventral frontostriatal pathway in fragile X syndrome. *Dev Med Child Neurol* **51:** 593–599.

Hanson JE, Madison DV. 2007. Presynaptic FMR1 genotype influences the degree of synaptic connectivity in a mosaic mouse model of Fragile X syndrome. *J Neurosci* **27:** 4014–4018.

Harlow EG, Till SM, Russell TA, Wijetunge LS, Kind P, Contractor A. 2010. Critical period plasticity is disrupted in the barrel cortex of FMR1 knockout mice. *Neuron* **65:** 385–398.

Hinds HL, Ashley CT, Sutcliffe JS, Nelson DL, Warren ST, Housman DE, Schalling M. 1993. Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome. *Nat Genet* **3:** 36–43.

Hu H, Qin Y, Bochorishvili G, Zhu Y, van Aelst L, Zhu JJ. 2008. Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome. *J Neurosci* **28:** 7847–7862.

Huber KM, Roder JC, Bear MF. 2001. Chemical induction of mGluR5- and protein synthesis-dependent long-term depression in hippocampal area CA1. *J Neurophysiol* **86:** 321–325.

Huber KM, Gallagher SM, Warren ST, Bear MF. 2002. Altered synaptic plasticity in a mouse model of fragile X mental retardation. *Proc Natl Acad Sci* **99:** 7746–7750.

Iacoangeli A, Rozhdestvensky TS, Dolzhanskaya N, Tournier B, Schutt J, Brosius J, Denman RB, Khandjian EW, Kindler S, Tiedge H. 2008. On BC1 RNA and the fragile X mental retardation protein. *Proc Natl Acad Sci* **105:** 734–739.

Ivanco TL, Greenough WT. 2002. Altered mossy fiber distributions in adult Fmr1 (FVB) knockout mice. *Hippocampus* **12:** 47–54.

Kaang BK. 1996. Parameters influencing ectopic gene expression in *Aplysia* neurons. *Neurosci Lett* **221:** 29–32.

Khandjian EW, Corbin F, Woerly S, Rousseau F. 1996. The fragile X mental retardation protein is associated with ribosomes. *Nat Genet* **12:** 91–93.

Kiledjian M, Dreyfuss G. 1992. Primary structure and binding activity of the hnRNP U protein: Binding RNA through RGG box. *EMBO J* **11:** 2655–2664.

Kirkpatrick LL, McIlwain KA, Nelson DL. 2001. Comparative genomic sequence analysis of the FXR gene family: FMR1, FXR1, and FXR2. *Genomics* **78:** 169–177.

Koekkoek SK, Yamaguchi K, Milojkovic BA, Dortland BR, Ruigrok TJ, Maex R, De Graaf W, Smit AE, VanderWerf F, Bakker CE, et al. 2005. Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome. *Neuron* **47:** 339–352.

Laggerbauer B, Ostareck D, Keidel EM, Ostareck-Lederer A, Fischer U. 2001. Evidence that fragile X mental retardation protein is a negative regulator of translation. *Hum Mol Genet* **10:** 329–338.

Larson J, Jessen RE, Kim D, Fine AK, du Hoffmann J. 2005. Age-dependent and selective impairment of long-term potentiation in the anterior piriform cortex of mice lacking the fragile X mental retardation protein. *J Neurosci* **25:** 9460–9469.

Lauterborn JC, Rex CS, Kramar E, Chen LY, Pandyarajan V, Lynch G, Gall CM. 2007. Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. *J Neurosci* **27:** 10685–10694.

Li Z, Zhang Y, Ku L, Wilkinson KD, Warren ST, Feng Y. 2001. The fragile X mental retardation protein inhibits translation via interacting with mRNA. *Nucleic Acids Res* **29:** 2276–2283.

Li J, Pelletier MR, Perez Velazquez JL, Carlen PL. 2002. Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. *Mol Cell Neurosci* **19:** 138–151.

Li C, Bassell GJ, Sasaki Y. 2009a. Fragile X mental retardation protein is involved in protein synthesis-dependent collapse of growth cones induced by semaphorin-3A. *Front Neural Circuits* **3:** 11.

Li HL, Huang BS, Vishwasrao H, Sutedja N, Chen W, Jin I, Hawkins RD, Bailey CH, Kandel ER. 2009b. Dscam mediates remodeling of glutamate receptors in *Aplysia* during de novo and learning-related synapse formation. *Neuron* **61:** 527–540.

Lim JH, Luo T, Sargent TD, Fallon JR. 2005. Developmental expression of *Xenopus* fragile X mental retardation-1 gene. *Int J Dev Biol* **49:** 981–984.

Martin KC, Zukin RS. 2006. RNA trafficking and local protein synthesis in dendrites: An overview. *J Neurosci* **26:** 7131–7134.

Maurer-Stroh S, Dickens NJ, Hughes-Davies L, Kouzarides T, Eisenhaber F, Ponting CP. 2003. The Tudor domain "Royal Family": Tudor, plant Agenet, Chromo, PWWP and MBT domains. *Trends Biochem Sci* **28:** 69–74.

Mazroui R, Huot ME, Tremblay S, Filion C, Labelle Y, Khandjian EW. 2002. Trapping of messenger RNA by Fragile X Mental Retardation protein into cytoplasmic granules induces translation repression. *Hum Mol Genet* **11:** 3007–3017.

Meredith RM, Holmgren CD, Weidum M, Burnashev N, Mansvelder HD. 2007. Increased threshold for spike-timing-dependent plasticity is caused by unreliable calcium signaling in mice lacking fragile X gene FMR1. *Neuron* **54:** 627–638.

Mineur YS, Sluyter F, de Wit S, Oostra BA, Crusio WE. 2002. Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse. *Hippocampus* **12:** 39–46.

Miyashiro KY, Beckel-Mitchener A, Purk TP, Becker KG, Barret T, Liu L, Carbonetto S, Weiler IJ, Greenough WT, Eberwine J. 2003. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. *Neuron* **37:** 417–431.

Montarolo PG, Goelet P, Castellucci VF, Morgan J, Kandel ER, Schacher S. 1986. A critical period for macromolecular synthesis in long-term heterosynaptic facilitation in *Aplysia*. *Science* **234:** 1249–1254.

Montarolo PG, Kandel ER, Schacher S. 1988. Long-term heterosynaptic inhibition in *Aplysia*. *Nature* **333:** 171–174.

Morales J, Hiesinger PR, Schroeder AJ, Kume K, Verstreken P, Jackson FR, Nelson DL, Hassan BA. 2002. *Drosophila* fragile X protein, DFXR, regulates neuronal morphology and function in the brain. *Neuron* **34:** 961–972.

Moroz LL, Edwards JR, Puthanveettil SV, Kohn AB, Ha T, Heyland A, Knudsen B, Sahni A, Yu F, Liu L, et al. 2006. Neuronal transcriptome of *Aplysia*: Neuronal compartments and circuitry. *Cell* **127:** 1453–1467.

Napoli I, Mercaldo V, Boyl PP, Eleuteri B, Zalfa F, De Rubeis S, Di Marino D, Mohr E, Massimi M, Falconi M, et al. 2008. The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. *Cell* **134:** 1042–1054.

Nosyreva ED, Huber KM. 2006. Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of Fragile X Syndrome. *J Neurophysiol* **95:** 3291–3295.

Ohno S. 1970. *Evolution by gene duplication*. Springer-Verlag, New York.

Paradee W, Melikian HE, Rasmussen DL, Kenneson A, Conn PJ, Warren ST. 1999. Fragile X mouse: Strain effects of knockout phenotype and evidence suggesting deficient amygdala function. *Neuroscience* **94:** 185–192.

Park S, Park JM, Kim S, Kim JA, Shepherd JD, Smith-Hicks CL, Chowdhury S, Kaufmann W, Kuhl D, Ryazanov AG, et al. 2008. Elongation factor 2 and fragile X mental retardation protein control the dynamic translation of Arc/Arg3.1 essential for mGluR-LTD. *Neuron* **59:** 70–83.

Penagarikano O, Mulle JG, Warren ST. 2007. The pathophysiology of fragile X syndrome. *Annu Rev Genomics Hum Genet* **8:** 109–129.

Pfeiffer BE, Huber KM. 2007. Fragile X mental retardation protein induces synapse loss through acute postsynaptic translational regulation. *J Neurosci* **27:** 3120–3130.

Pittenger C, Kandel ER. 2003. In search of general mechanisms for long-lasting plasticity: *Aplysia* and the hippocampus. *Philos Trans R Soc Lond B Biol Sci* **358:** 757–763.

Ramos A, Hollingworth D, Adinolfi S, Castets M, Kelly G, Frenkiel TA, Bardoni B, Pastore A. 2006. The structure of the N-terminal domain of the fragile X mental retardation protein: A platform for protein–protein interaction. *Structure* **14:** 21–31.

Rayport SG, Schacher S. 1986. Synaptic plasticity in vitro: Cell culture of identified *Aplysia* neurons mediating short-term habituation and sensitization. *J Neurosci* **6:** 759–763.

Sambrook J, Fritsch EF, Maniatis T. 1989. *Molecular cloning: A laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

Schenck A, Bardoni B, Moro A, Bagni C, Mandel JL. 2001. A highly conserved protein family interacting with the fragile X mental retardation protein (FMRP) and displaying selective interactions with FMRP-related proteins FXR1P and FXR2P. *Proc Natl Acad Sci* **98:** 8844–8849.

Shang Y, Wang H, Mercaldo V, Li X, Chen T, Zhuo M. 2009. Fragile X mental retardation protein is required for chemically-induced long-term potentiation of the hippocampus in adult mice. *J Neurochem* **111:** 635–646.

Siomi MC, Siomi H, Sauer WH, Srinivasan S, Nussbaum RL, Dreyfuss G. 1995. FXR1, an autosomal homolog of the fragile X mental retardation gene. *EMBO J* **14:** 2401–2408.

Siomi H, Ishizuka A, Siomi MC. 2004. RNA interference: A new mechanism by which FMRP acts in the normal brain? What can *Drosophila* teach us? *Ment Retard Dev Disabil Res Rev* **10:** 68–74.

Snyder EM, Philpot BD, Huber KM, Dong X, Fallon JR, Bear MF. 2001. Internalization of ionotropic glutamate receptors in response to mGluR activation. *Nat Neurosci* **4:** 1079–1085.

Stefani G, Fraser CE, Darnell JC, Darnell RB. 2004. Fragile X mental retardation protein is associated with translating polyribosomes in neuronal cells. *J Neurosci* **24:** 7272–7276.

Stock DW, Quattro JM, Whitt GS, Powers DA. 1997. Lactate dehydrogenase (LDH) gene duplication during chordate evolution: The cDNA sequence of the LDH of the tunicate *Styela plicata*. *Mol Biol Evol* **14:** 1273–1284.

Tamanini F, Meijer N, Verheij C, Willems PJ, Galjaard H, Oostra BA, Hoogeveen AT. 1996. FMRP is associated to the ribosomes via RNA. *Hum Mol Genet* **5:** 809–813.

Tucker B, Richards R, Lardelli M. 2004. Expression of three zebrafish orthologs of human FMR1-related genes and their phylogenetic relationships. *Dev Genes Evol* **214:** 567–574.

Valverde R, Pozdnyakova I, Kajander T, Venkatraman J, Regan L. 2007. Fragile X mental retardation syndrome: Structure of the KH1–KH2 domains of fragile X mental retardation protein. *Structure* **15:** 1090–1098.

Verkerk AJ, de Graaff E, De Boulle K, Eichler EE, Konecki DS, Reyniers E, Manca A, Poustka A, Willems PJ, Nelson DL, et al. 1993. Alternative splicing in the fragile X gene FMR1. *Hum Mol Genet* **2:** 399–404.

Wan L, Dockendorff TC, Jongens TA, Dreyfuss G. 2000. Characterization of dFMR1, a *Drosophila melanogaster* homolog of the fragile X mental retardation protein. *Mol Cell Biol* **20:** 8536–8547.

Wang DO, Kim SM, Zhao Y, Hwang H, Miura SK, Sossin WS, Martin KC. 2009. Synapse- and stimulus-specific local translation during long-term neuronal plasticity. *Science* **324:** 1536–1540.

Waung MW, Pfeiffer BE, Nosyreva ED, Ronesi JA, Huber KM. 2008. Rapid translation of Arc/Arg3.1 selectively mediates mGluR-dependent LTD through persistent increases in AMPAR endocytosis rate. *Neuron* **59:** 84–97.

Wilson BM, Cox CL. 2007. Absence of metabotropic glutamate receptor-mediated plasticity in the neocortex of fragile X mice. *Proc Natl Acad Sci* **104:** 2454–2459.

Xie W, Dolzhanskaya N, LaFauci G, Dobkin C, Denman RB. 2009. Tissue and developmental regulation of fragile X mental retardation 1 exon 12 and 15 isoforms. *Neurobiol Dis* **35:** 52–62.

Zakharenko SS, Zablow L, Siegelbaum SA. 2002. Altered presynaptic vesicle release and cycling during mGluR-dependent LTD. *Neuron* **35:** 1099–1110.

Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S, Oostra B, Bagni C. 2003. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. *Cell* **112:** 317–327.

Zalfa F, Eleuteri B, Dickson KS, Mercaldo V, De Rubeis S, di Penta A, Tabolacci E, Chiurazzi P, Neri G, Grant SG, et al. 2007. A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. *Nat Neurosci* **10:** 578–587.

Zang JB, Nosyreva ED, Spencer CM, Volk LJ, Musunuru K, Zhong R, Stone EF, Yuva-Paylor LA, Huber KM, Paylor R, et al. 2009. A mouse model of the human Fragile X syndrome I304N mutation. *PLoS Genet* **5:** e1000758. doi: 10.1371/journal.pgen.1000758.

Zhang Y, O'Connor JP, Siomi MC, Srinivasan S, Dutra A, Nussbaum RL, Dreyfuss G. 1995. The fragile X mental retardation syndrome protein interacts with novel homologs FXR1 and FXR2. *EMBO J* **14:** 5358–5366.

Zhang YQ, Bailey AM, Matthies HJ, Renden RB, Smith MA, Speese SD, Rubin GM, Broadie K. 2001. *Drosophila* fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. *Cell* **107:** 591–603.

Zhang J, Hou L, Klann E, Nelson DL. 2009. Altered hippocampal synaptic plasticity in the FMR1 gene family knockout mouse models. *J Neurophysiol* **101:** 2572–2580.

Zhao MG, Toyoda H, Lee YS, Wu LJ, Ko SW, Zhang XH, Jia Y, Shum F, Xu H, Li BM, et al. 2005. Roles of NMDA NR2B subtype receptor in prefrontal long-term potentiation and contextual fear memory. *Neuron* **47:** 859–872.